Viralytics announces International Institutional ownership

THE PHARMACY: Viralytics Limited (ASX: VLA) has completed a $27.1
million equity offering that included a number of new institutional
investors who specialize in healthcare.

The offering was finalised after approval by shareholders at the company’s general meeting on 6 March 2014.

The major participants in the placement were United States-based
Cormorant Asset Management, which now holds an 8.9 per cent stake in
Viralytics;

BVF Partners L.P., also located in the United States (6.7 per cent);

Abingworth, headquartered in the United Kingdom (6.1 per cent);

Sabby Capital, headquartered in the United States (5.8 per cent); and

Hunter Hall, located in Australia (4.9 per cent).

The capital raised will fully fund the company through 2016, including its expanding clinical trial program.

Viralytics currently has a Phase 2 study and a Phase 1/2 trial ongoing
with an additional randomised Phase 2 melanoma clinical trial in the
planning stage.

The studies are evaluating the company’s lead product CAVATAK™ in
late-stage cancer patients and will provide important data to guide its
further development.

Website: www.viralytics.com